Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
237.45
+7.90 (3.44%)
At close: May 19, 2026, 4:00 PM EDT
238.57
+1.12 (0.47%)
After-hours: May 19, 2026, 7:50 PM EDT

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Total Neuroscience Revenue
2.96B2.88B2.70B
Total Neuroscience Revenue Growth
2.92%6.68%-0.35%
Total Oncology Revenue
1.23B1.13B1.11B
Total Oncology Revenue Growth
9.16%1.60%9.47%
Other Product Revenue
12.56M14.17M11.47M
Other Product Revenue Growth
-11.38%23.55%-17.15%
Total Product Revenue, Net
4.21B4.02B3.82B
Total Product Revenue, Net Growth
4.62%5.25%2.25%
High-Sodium Oxybate AG Royalty Revenue
199.08M211.73M217.58M
High-Sodium Oxybate AG Royalty Revenue Growth
-5.97%-2.69%186.59%
Other Royalty and Contract Revenue
31.84M34.01M30.21M
Other Royalty and Contract Revenue Growth
-6.40%12.58%41.55%
Total Royalties and Contract Revenue
230.91M245.74M247.79M
Total Royalties and Contract Revenue Growth
-6.03%-0.83%154.76%
Revenue (Other)
6.00K3.00K4.00K
Revenue (Total)
4.44B4.27B4.07B
Revenue (Total) Growth
4.01%4.88%6.12%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
United States Revenue
3.99B3.83B3.66B
United States Revenue Growth
4.21%4.69%4.88%
Europe Revenue
350.48M341.12M312.71M
Europe Revenue Growth
2.74%9.09%16.14%
All Other Countries Revenue
95.28M94.87M96.14M
All Other Countries Revenue Growth
0.43%-1.32%28.21%
Revenue (Other)
9.00K2.00K-1.00K
Revenue (Total)
4.44B4.27B4.07B
Revenue (Total) Growth
4.01%4.88%6.12%
Updated May 5, 2026. Data Source: Fiscal.ai.